Molecule
Tradipitant is a prescription medicine indicated for the prevention of vomiting induced by motion in adults. It is available as capsules for oral use. MedsAcross supplies Tradipitant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults.
Source: US FDA prescribing information
Tradipitant is a selective, high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Tradipitant does not have affinity for NK2 and NK3 receptors, serotonin (5-HT3), dopamine (D2), cholinergic, or histamine (H1) receptors. Tradipitant has been shown in animal models to inhibit drug induced emesis. Human Positron Emission Tomography (PET) studies with tradipitant have shown that tradipitant crosses the blood brain barrier and occupies brain NK-1 receptors. The exact mechanism by which tradipitant exerts its therapeutic effect is not fully established.
Source: US FDA prescribing information
The recommended dosage of NEREUS is 85 mg or 170 mg as a single oral dose approximately 60 minutes before an event expected to cause vomiting induced by motion. The safety of NEREUS for the prevention of vomiting induced by motion in adults for more than 90 doses has not been established in clinical trials. The maximum dosage in a 24-hour period is a single dose of 85 mg or 170 mg. Administer on an empty stomach, at least 1 hour prior to or 2 hours after a full meal.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Effects on the Ability to Drive or Operate Machinery: May impair mental and/or physical abilities required for driving a motor vehicle or operating heavy machinery. Concomitant use of other drugs that cause central nervous system depression and strong CYP3A4 inhibitors may increase this effect. If concomitant use is unavoidable, warn patients against driving and other activities requiring complete mental alertness.
Source: US FDA prescribing information
Most common adverse reactions (incidence ≥5%) are: somnolence, headache, and fatigue.
Source: US FDA prescribing information
Strong CYP3A4 Inhibitors: May increase tradipitant exposure and the risk of adverse reactions. Effects of Other Drugs on NEREUS Strong CYP3A4 Inhibitors Tradipitant is a CYP3A4 substrate. Strong CYP3A4 inhibitors may increase tradipitant exposure, which may increase the risk of adverse reactions to NEREUS.
Source: US FDA prescribing information
Store NEREUS capsules at controlled room temperature, 25°C (77°F), excursions permitted to 15°C to 30°C (59° - 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Tradipitant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Nereus 85 mg capsuleOral | Vanda Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 December 2025 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Tradipitant in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Tradipitant and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Tradipitant, including Nereus.
Yes. The US FDA first approved Tradipitant on 30 December 2025, according to Drugs@FDA.
No listed presentation of Tradipitant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.